Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma hepG2 cells

Cellular Physiology and Biochemistry

Volumn 9, Issue 3, 1999, Pages 139-149

  Clavey, V ^a,b   Copin, C ^a   Mariotte, M C ^a   Bauge E ^a   Chinetti, G ^a   Fruchart, J ^a   Fruchart, J C ^a   Dallongeville, J ^a   Staels, B ^a  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoproteins; Fibrates; Gene expression; Peroxisome proliferator activated receptor

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIRINIXIC ACID; ROSIGLITAZONE; TRIACYLGLYCEROL;

ARTICLE; CELL DENSITY; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR DOWN REGULATION;

EID: 0032819192     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016311     Document Type: Article

References (45)

1. Mahley RW: Plasma lipoprotein: Apolipoprotein structure and function. J Lipid Res 1984;25:1277-1294.
2. Luc G, Fievet C, Arveiler D, Evans A, Bard JM, Cambien F, Fruchart JC, Ducimetière P: Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: The ECTIM Study. J Lipid Res 1996;37:508-517.
3. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV: Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and A-I. Evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-1295.
4. Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L: Apolipoprotein C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989; 77:139-149.
5. Dallongeville J, Bauge E, Lebel P, Fruchart JC: Fat ingestion is associated with increased levels of apoC-III- and apoE-B-containing lipoprotein particles in humans. Eur J Clin Invest 1997;27:1055-1060.
6. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL: Hypertrigly-ceridemia as a result of human apolipoprotein CIII gene expression in transgenic mice. Science 1990;249: 790-793.
7. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL: Mechanism of hypertriglyceridemia in human apo CIII transgenic mice: Diminished VLDL fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889-1990.
8. Maeda N, Lee D, Oliver P, Quarford SH, Osada J: Targeted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from post-prandial hypertriglyceridemia. J Biol Chem 1994;269:23610-23616.
9. Agnani G, Bard JM, Candelier L, Delattre S, Fruchart JC, Clavey V: Interaction of LpB:E, LpB:C-III and LpB:C-III:E lipoproteins with the low density lipoprotein receptor on HeLa cells. Arteriosclerosis 1991; 11:1021-1029.
10. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC: Modulation of lipoprotein binding to the LDL receptor by exogenous lipids and apolipoproteins C-I, C-II, C-III and E. Arteriosclerosis 1995;15: 963-971.
11. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson D, Norum R, Brown WV: Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein CIII and AI. J Clin Invest 1986;78:1287-1295.
12. Gruber PJ, Torres-Rosaro A, Wolak ML, Leff T: Apolipoprotein CIII gene transcription is regulated by a cytokine-inducible NF-kappa B element. Nucleic Acids Res 1994;22: 2417-2422.
13. Chen M, Breslow JL, Li W, Leff T: Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: Correlation with changes in plasma triglycerides levels. J Lipid Res 1994;35:1918-1924.
14. Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC: Changes in lipoprotein particles defined by their apolipoprotein composition on pravastatin and cholestyramine therapy. J Drug Dev 1990;3:111-115.
15. Bard JM, Luc G, Douste-Blazy P, Drouin P, Ziegler O, Jacotot B, Dachet C. De Gennes JL, Fruchart JC: Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolemia. Eur J Clin Pharmacol 1989;37:545-550.
16. Haubenwallner S, Essenbourg AD, Barnett BC, Pape ME, Demattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T, Bisgaier CL: Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action. J Lipid Res 1995;36:2541-2551.
17. Hertz R, Bishara-Shieban J, Bar-Tana J: Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995;270: 13470-13475.
18. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997;272: 27307-27312.
19. Hertz R, Arnon J, Hoter A, Shouval D, Bar-Tana J: Clofibrate does not induce peroxisomal proliferation in human hepatoma cell lines PLC/ PRF/5 and SK-HEP-1. Cancer Lett 1987;34:263-272.
20. Staels B, Vu Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J: Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-712.
21. Tam PS, Archer TK, Deeley RG: Effects of oestrogen on apolipoprotein secretion by the human hepatocarcinoma cell line, HepG2. J Biol Chem 1985;260:1670-1675.
22. Zannis VI, Brewslow JL, San Giacomo TR, Aden DP, Knowles BB: Characterization of the major apolipoproteins secreted by two human hepatoma cell lines. Biochemistry 1981;20:7089-7096.
23. Dashti N. Wolfbauer G, Secretion of lipids, apolipoproteins, and lipoproteins by human hepatoma cell line, HepG2: Effects of oleic acid and insulin. J Lipid Res 1987;28:423-436.
24. Dixon JL, Ginsberg HN: Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells. J Lipid Res 1993;34:167-179.
25. Haghpassand M, Wilder D, Moberly JB: Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J Lipid Res 1996;37:1468-1480.
26. Passilly P, Jannin B, Hassel SJ, Latruffe N: Human HepG2 and rat Fao hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: Analysis by flow cytometry. Exp Cell Res 1996; 223:436-442.
27. Ladias JA, Hadzopoulou-Cladaras M, Cardot P, Cheng J, Zannis VI, Cladaras C: Transcriptional regulation of human apolipoprotein genes apoB, apoCIII, and apoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 1992; 267:15849-15860.
28. Benoist F, Grand-Perret T: A sensitive method to analyze in vitro secretion of lipoproteins: Distribution of apolipoproteins is modulated by oleic acid in HepG2 cells. J Lipid Res 1995;36:2243-2250.
29. Tam SP: Effect of ethanol on lipoprotein secretion in two human hepatoma cell lines, HepG2 and Hep3B. Alcohol Clin Exp Res 1992; 16:1021-1028.
30. Parsy D, Clavey V, Fievet C, Kora I, Duriez P, Fruchart JC: Quantification of apolipoprotein CIII in serum by noncompetitive immunoenzymometric assay. Clin Chem 1987; 31:1632-1635.
31. Leroy A, Vu Dac N, Koffigan M, Clavey V, Fruchart JC: Characterization of monoclonal antibody that binds to apo E and lipoprotein of human plasma containing apo E. Applications to ELISA quantification of plasma apo E. J Immunoassay 1988;9:309-334.
32. Puchois P, Kandoussi A, Duriez P, Fruchart JC, McConathy WJ, Koren E: Quantitative determination of human plasma apo-AII by a non-competitive enzyme-linked immunosorbent assay. J Immunoassay 1986;7:285-307.
33. Betard C, Vu-Dac N, Mezdour H, Nestruck AC, Leroy A, Fruchart JC: Standardization of an enzymometric assay for apolipoprotein A-I by using mixtures of monoclonal antibodies. J Clin Chem Clin Biochem 1987;25:893-899.
34. Fievet C, Dedieu A, Kandoussi A, Luyeye I, Fruchart JC: Quantitation of human serum apolipoprotein B by enzyme immunoassay in excess antigen. Clin Chim Acta 1986;159: 269-278.
35. Masiakowski PR, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line. Nucleic Acids Res 1982;10: 7895-7903.
36. Laborda J: 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991;19:3998.
37. Staels B, Auwerx J: Perturbation of developmental gene expression in rat liver by fibric acid derivatives: Lipoprotein lipase and alpha-feto-protein as models. Development 1992;115:1035-1043.
38. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-25580.
39. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R. Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidai H, Auwerx J: The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997;272:18779-18789.
40. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B: Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. Arterioscler Thromb Vase Biol 1997;17:1756-1764.
41. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-gamma (PPARγ). J Biol Chem 1995;270: 12953-12956.
42. Furth EE, Sprecher H, Fisher EA, Fleishman HD, Laposata M: An in vitro model for essential fatty acid deficiency: HepG2 cells permanently maintained in lipid-free medium. J Lipid Res 1992;33:1719-1726.
43. Nishiyama C, Hi R, Osada S, Osumi T: Functional interactions between nuclear receptors recognizing a common sequence element, the direct repeat motif spaced by one nucleotide (DR-1). J Biochem (Tokyo) 1998;123:1174-1179.
44. Fraser JD, Martinez V, Straney R, Briggs MR: DNA binding and transcription activation specificity of hepatocyte nuclear factor 4. Nucleic Acids Res 1998;26:2702-2707.
45. Taylor DG, Haubenwallner S, Leff T: Characterization of a dominant negative mutant form of the HNF-4 orphan receptor. Nucleic Acids Res 1996;24:2930-2935.